Citigroup Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $102 Citigroup Maintains Buy on Snowflake, Raises Price Target to $310 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback